NewTimeSpace News: On 18 August 2026, ALPHAMAB-B (09966.HK) announced that the NDA for Anbenitamab (KN026) plus HB1801 as first-line treatment for HER2-positive advanced breast cancer has been accepted by the NMPA under priority review; the pivotal Phase III study demonstrated significantly superior progression-free survival versus the standard of care.
NewTimeSpace News: On 18 August 2026, CSPC PHARMA (01093.HK) announced that the NDA for KN026 plus HB1801 as first-line treatment for HER2-positive advanced breast cancer has been accepted by the NMPA under priority review; the pivotal Phase III study showed significantly superior progression-free survival versus the standard of care.
On August 18, 2026, The Hang Seng Index rose 0.07%, the Hang Seng TECH Index fell 0.90%, and the Hang Seng China Enterprises Index edged up 0.16%. The Hong Kong market's total turnover was HK$255.5 billion, with southbound funds recording a net inflow of HK$14.001 billion.The large-model segment remained under pressure, with the two front-runners plunging: Z.AI (02513.HK) fell 13.30% and MINIMAX-W (00100.HK) fell 4.49%. TENCENT, MEITUAN-W and others continued to weaken, while ALIBABA-W (09988.HK) rose against the trend by 3.68%.
NewTimeSpace News: On 18 August 2026, HBM HOLDINGS-B (02142.HK) voluntarily announced that the IND application of HBM7004, a novel B7H4xCD3 bispecific antibody for advanced solid tumors, has been approved by the NMPA, following the FDA's permission for a US Phase I trial; developed from the Company's proprietary HBICE® platform, HBM7004 demonstrated robust anti-tumor efficacy in preclinical studies.
NewTimeSpace News: On August 18, 2026, BIDU-SW (09888.HK) edged higher in the afternoon session. As of 15:41, the stock was quoted at HK$101.30, representing a 1.00% gain.
newtimespace reported, on August 18, 2026, the chip theme weakened, with ASMPT (00522.HK) falling in intraday fluctuations. As of 13:35, the stock was quoted at HK$173.600, down 4.67%.
newtimespace reported, on August 18, 2026, the robotics theme weakened, with Xiaomi-W (01810.HK) falling in intraday fluctuations. As of 13:14, the stock was quoted at HK$25.480, down 1.55%.
NewTimeSpace News: On 18 August 2026, CANBRIDGE-B (01228.HK) announced that maralixibat oral solution has been approved by the National Health Insurance Administration of Taiwan, China for NHI coverage in treating both ALGS and PFIC, effective 1 September 2026. Maralixibat is the first approved drug for ALGS and PFIC in Taiwan, China, holding FDA Breakthrough Therapy designation and orphan drug designations across multiple jurisdictions. The company views the inclusion as an important milestone in its rare disease commercialization that will substantially reduce the financial burden on patient families.
NewTimeSpace News: On 17 August 2026, HAIXI PHARMA (02637.HK) announced that its self-developed oral small-molecule innovative drug HX9428 has been granted Fast Track Designation by the US FDA for the treatment of neovascular age-related macular degeneration (nAMD); HX9428 has completed Phase I clinical studies, is advancing Phase II studies, and has received FDA approval to conduct a Phase II clinical trial in the United States.
NewTimeSpace News: On 17 August 2026, MICOT PHARMA-B (02335.HK) announced that three studies on its key product XTL6001 have been accepted for presentation at international academic conferences: two abstracts were accepted at EASD 2026 (including an oral presentation and a short oral discussion) and one at ASN Kidney Week 2026 as a poster; XTL6001 is a GLP-1R/GCGR/MasR triple-target agonist approved for clinical studies in both China and the US, being developed for weight management, proteinuric CKD and MASH.
NewTimeSpace News: On 17 August 2026, BAIYUNSHAN PH (00874.HK) announced that its controlling subsidiary Tianxin Pharmaceutical's Cefazolin Sodium for Injection (0.5g, 1.0g) has obtained the Pharmaceutical Registration Certificate issued by the Macao SAR Government Pharmaceutical Administration Bureau, and will be sold in Macao by Guangyao International (Macao) under authorization; the drug has passed the national generic consistency evaluation, and the certificate has no material impact on the Company's current-period performance.
On August 17, 2026, the Hang Seng Index rose 1.34%, the Hang Seng TECH Index rose 1.58%, and the Hang Seng China Enterprises Index rose 1.19%. The Hang Seng Index recorded a turnover of HK$210.8 billion, with southbound (mainland) funds posting a net inflow of HK$3.077 billion.The AI chip and hardware direction surged across the board, becoming the main driver of the day's rebound. Iluvatar CoreX (09903.HK) rose 10.68%, Montage Technology (06809.HK) rose 9.58%, and GigaDevice, HUA HONG GRACE, Biren Technology, and SMIC posted sharp gains.
NewTimeSpace News: On 17 August 2026, HONY MEDIA (00419.HK) voluntarily announced that its subsidiary has signed a five-year cooperation agreement with Longfor Property Services to jointly build and operate the "Longfor Property Robot Operation Platform" based on the AIROBO operating system, with the Chengdu Xichen Yuanshu pilot project having commenced trial operation; Longfor Property Services is a wholly-owned subsidiary of Longfor Group (00960.HK) with approximately 360 million square meters under management.
NewTimeSpace News: On August 17, 2026, RoboSense (02498.HK) trended stronger in the afternoon. As of 15:13, the stock traded at HK$22.42, up 1.26%.
newtimespace reported, as of 14:00 on August 17, 2026, Penghua CNI Grain Industry ETF (159698) rose 3.39%, with the latest price at RMB 0.89.In terms of scale, the ETF's assets grew by RMB 32.4295 million over the past 2 weeks, a notable increase, with its newly added scale ranking 1st out of 9 among comparable funds.In terms of shares, the ETF's latest shares reached 1.151 billion, a near-3-month high, ranking 1st out of 9 among comparable funds.
newtimespace reported, on August 17, 2026, chip-related themes strengthened sharply, with SMIC (00981.HK) surging in intraday fluctuations. As of 13:33, the stock was quoted at HK$75.550, up 6.71%.
